Chemical suppression of an oncogenic splicing variant of AIMP2 induces tumour regression

Hee Sook Lee, Dae Gyu Kim, Young Sun Oh, Nam Hoon Kwon, Jin Young Lee, Doyeun Kim, Song Hwa Park, Jong Hwan Song, Sunkyung Lee, Jung Min Han, Bum Joon Park, Jongkook Lee, Sunghoon Kim

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

AIMP2 (aminoacyl-tRNA synthetase-interacting multifunctional protein 2) is a potent tumour suppressor that induces apoptosis in response to various oncogenic signals. AIMP2-DX2, an exon2-deleted splicing variant of AIMP2, is up-regulated in lung cancer and competitively suppresses the pro-apoptotic activity of AIMP2, resulting in tumorigenesis. In the present study we report that BC-DXI01, a synthetic compound, specifically reduces the cellular levels of AIMP2-DX2 through selective degradation of the AIMP2-DX2 mRNA transcript. We found that BC-DXI01-mediated cell death positively correlates with AIMP2-DX2 expression in the lung cancer cell lines tested. Administration of BC-DXI01 in a AIMP2-DX2-driven tumour xenograft mice model led to reduced tumour sizes and volumes of up to 60% in comparison with vehicle-treated mice group, consistent with decreases in AIMP2-DX2 transcript and protein levels. Taken together, our findings suggest that tumorigenic activity of AIMP2-DX2 can be controlled by the small chemical BC-DXI01, which can selectively suppress the AIMP2-DX2 mRNA transcript.

Original languageEnglish
Pages (from-to)411-416
Number of pages6
JournalBiochemical Journal
Volume454
Issue number3
DOIs
Publication statusPublished - 2013 Sep 15

Fingerprint

Amino Acyl-tRNA Synthetases
Tumors
Neoplasms
Proteins
Lung Neoplasms
Messenger RNA
Cell death
Tumor Burden
Heterografts
Carcinogenesis
Cell Death

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Lee, H. S., Kim, D. G., Oh, Y. S., Kwon, N. H., Lee, J. Y., Kim, D., ... Kim, S. (2013). Chemical suppression of an oncogenic splicing variant of AIMP2 induces tumour regression. Biochemical Journal, 454(3), 411-416. https://doi.org/10.1042/BJ20130550
Lee, Hee Sook ; Kim, Dae Gyu ; Oh, Young Sun ; Kwon, Nam Hoon ; Lee, Jin Young ; Kim, Doyeun ; Park, Song Hwa ; Song, Jong Hwan ; Lee, Sunkyung ; Han, Jung Min ; Park, Bum Joon ; Lee, Jongkook ; Kim, Sunghoon. / Chemical suppression of an oncogenic splicing variant of AIMP2 induces tumour regression. In: Biochemical Journal. 2013 ; Vol. 454, No. 3. pp. 411-416.
@article{0bf263172813466599f5a17e9fbe74e9,
title = "Chemical suppression of an oncogenic splicing variant of AIMP2 induces tumour regression",
abstract = "AIMP2 (aminoacyl-tRNA synthetase-interacting multifunctional protein 2) is a potent tumour suppressor that induces apoptosis in response to various oncogenic signals. AIMP2-DX2, an exon2-deleted splicing variant of AIMP2, is up-regulated in lung cancer and competitively suppresses the pro-apoptotic activity of AIMP2, resulting in tumorigenesis. In the present study we report that BC-DXI01, a synthetic compound, specifically reduces the cellular levels of AIMP2-DX2 through selective degradation of the AIMP2-DX2 mRNA transcript. We found that BC-DXI01-mediated cell death positively correlates with AIMP2-DX2 expression in the lung cancer cell lines tested. Administration of BC-DXI01 in a AIMP2-DX2-driven tumour xenograft mice model led to reduced tumour sizes and volumes of up to 60{\%} in comparison with vehicle-treated mice group, consistent with decreases in AIMP2-DX2 transcript and protein levels. Taken together, our findings suggest that tumorigenic activity of AIMP2-DX2 can be controlled by the small chemical BC-DXI01, which can selectively suppress the AIMP2-DX2 mRNA transcript.",
author = "Lee, {Hee Sook} and Kim, {Dae Gyu} and Oh, {Young Sun} and Kwon, {Nam Hoon} and Lee, {Jin Young} and Doyeun Kim and Park, {Song Hwa} and Song, {Jong Hwan} and Sunkyung Lee and Han, {Jung Min} and Park, {Bum Joon} and Jongkook Lee and Sunghoon Kim",
year = "2013",
month = "9",
day = "15",
doi = "10.1042/BJ20130550",
language = "English",
volume = "454",
pages = "411--416",
journal = "Biochemical Journal",
issn = "0264-6021",
publisher = "Portland Press Ltd.",
number = "3",

}

Lee, HS, Kim, DG, Oh, YS, Kwon, NH, Lee, JY, Kim, D, Park, SH, Song, JH, Lee, S, Han, JM, Park, BJ, Lee, J & Kim, S 2013, 'Chemical suppression of an oncogenic splicing variant of AIMP2 induces tumour regression', Biochemical Journal, vol. 454, no. 3, pp. 411-416. https://doi.org/10.1042/BJ20130550

Chemical suppression of an oncogenic splicing variant of AIMP2 induces tumour regression. / Lee, Hee Sook; Kim, Dae Gyu; Oh, Young Sun; Kwon, Nam Hoon; Lee, Jin Young; Kim, Doyeun; Park, Song Hwa; Song, Jong Hwan; Lee, Sunkyung; Han, Jung Min; Park, Bum Joon; Lee, Jongkook; Kim, Sunghoon.

In: Biochemical Journal, Vol. 454, No. 3, 15.09.2013, p. 411-416.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Chemical suppression of an oncogenic splicing variant of AIMP2 induces tumour regression

AU - Lee, Hee Sook

AU - Kim, Dae Gyu

AU - Oh, Young Sun

AU - Kwon, Nam Hoon

AU - Lee, Jin Young

AU - Kim, Doyeun

AU - Park, Song Hwa

AU - Song, Jong Hwan

AU - Lee, Sunkyung

AU - Han, Jung Min

AU - Park, Bum Joon

AU - Lee, Jongkook

AU - Kim, Sunghoon

PY - 2013/9/15

Y1 - 2013/9/15

N2 - AIMP2 (aminoacyl-tRNA synthetase-interacting multifunctional protein 2) is a potent tumour suppressor that induces apoptosis in response to various oncogenic signals. AIMP2-DX2, an exon2-deleted splicing variant of AIMP2, is up-regulated in lung cancer and competitively suppresses the pro-apoptotic activity of AIMP2, resulting in tumorigenesis. In the present study we report that BC-DXI01, a synthetic compound, specifically reduces the cellular levels of AIMP2-DX2 through selective degradation of the AIMP2-DX2 mRNA transcript. We found that BC-DXI01-mediated cell death positively correlates with AIMP2-DX2 expression in the lung cancer cell lines tested. Administration of BC-DXI01 in a AIMP2-DX2-driven tumour xenograft mice model led to reduced tumour sizes and volumes of up to 60% in comparison with vehicle-treated mice group, consistent with decreases in AIMP2-DX2 transcript and protein levels. Taken together, our findings suggest that tumorigenic activity of AIMP2-DX2 can be controlled by the small chemical BC-DXI01, which can selectively suppress the AIMP2-DX2 mRNA transcript.

AB - AIMP2 (aminoacyl-tRNA synthetase-interacting multifunctional protein 2) is a potent tumour suppressor that induces apoptosis in response to various oncogenic signals. AIMP2-DX2, an exon2-deleted splicing variant of AIMP2, is up-regulated in lung cancer and competitively suppresses the pro-apoptotic activity of AIMP2, resulting in tumorigenesis. In the present study we report that BC-DXI01, a synthetic compound, specifically reduces the cellular levels of AIMP2-DX2 through selective degradation of the AIMP2-DX2 mRNA transcript. We found that BC-DXI01-mediated cell death positively correlates with AIMP2-DX2 expression in the lung cancer cell lines tested. Administration of BC-DXI01 in a AIMP2-DX2-driven tumour xenograft mice model led to reduced tumour sizes and volumes of up to 60% in comparison with vehicle-treated mice group, consistent with decreases in AIMP2-DX2 transcript and protein levels. Taken together, our findings suggest that tumorigenic activity of AIMP2-DX2 can be controlled by the small chemical BC-DXI01, which can selectively suppress the AIMP2-DX2 mRNA transcript.

UR - http://www.scopus.com/inward/record.url?scp=84883383447&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883383447&partnerID=8YFLogxK

U2 - 10.1042/BJ20130550

DO - 10.1042/BJ20130550

M3 - Article

C2 - 23815603

AN - SCOPUS:84883383447

VL - 454

SP - 411

EP - 416

JO - Biochemical Journal

JF - Biochemical Journal

SN - 0264-6021

IS - 3

ER -